Transpharmation Ltd. ’s Post

⚡️ 𝗔𝗘𝗗 𝗿𝗲𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗰𝗼𝗺𝗽𝗼𝘂𝗻𝗱 𝘀𝘁𝘂𝗱𝘆 𝘀𝗲𝗿𝗶𝗲𝘀: #2 - 𝐏𝐞𝐧𝐭𝐲𝐥𝐞𝐧𝐞𝐭𝐞𝐭𝐫𝐚𝐳𝐨𝐥𝐞 (𝐏𝐓𝐙) At Neuroservices-Alliance, we are experts in assessing the effects of potential antiepileptic drugs (AEDs). PTZ is a critical compound used to induce seizures in preclinical models, providing essential insights for epilepsy research. Our findings reveal that PTZ decreases epileptiform discharge (ED) rate while increasing ED amplitude, making it invaluable for understanding seizure mechanisms and evaluating AED efficacy. 🔎 Interested in how we can enhance your AED research? Reach out to us: contact@neuroservices-alliance.com 🔗 Discover more in our detailed article: https://lnkd.in/d5gq5emb   #Epilepsy #Neuroscience #CNS #Research #drugdiscovery #PTZ #AED #Research

Cellular models of neurodegenerative diseases play an integral role in preclinical drug discovery, and safety studies. Patient iPSC-derived dopamine neurons along with Multi-Electrode Array (MEA) assay provide a useful platform to investigate functional phenotypes both at the individual neuron and network levels. CRL now offers testing of small molecules aimed at reversing pathophysiology linked with cellular models of neurodegenerative diseases. For more details contact our client service https://lnkd.in/eGbNJsNC or connect with our specialists Amit Kumar Chouhan, PhD, Eddie Burns and Dario Magnani #CharlesRiver #drugdevelopment #Pharmacology #neuroscience #drugdiscovery #neurology #neurodegeneration #parkinsonsdisease Follow us at Discovery | Charles River

🧠 During #BrainAwarenessWeek we want to celebrate the remarkable advancements in neuroscience, and diseases of the central nervous system (#CNS).   At Secarna Pharmaceuticals, our focus on developing antisense oligonucleotides (ASOs) presents a promising avenue for treating these complex conditions. Through precision targeting of genetic sequences implicated in neurodegenerative diseases, ASOs offer a transformative approach.   Combining our proprietary ASO discovery and development platform with our partner’s expertise, such as Denali Therapeutics and SciNeuro Pharmaceuticals, allow us to accelerate the pace of innovation. Together, we're committed to bringing hope and tangible solutions to patients and families impacted by neurodegenerative diseases. 🤝💪   #BrainAwarenessWeek #Neuroscience #ASOs #Collaboration

Seismic Therapeutic – Preclinical Data for Novel Immunoglobulin Sculpting Enzyme to treat chronic and acute autoantibody mediated diseases, including the chronic neuromuscular autoimmune disorder https://lnkd.in/dQ-UGGTd #autoimmunedisease #pharmaindustry #neuroscience Seismic Therapeutic

Lysosome Clustering Drugs Promote Autophagy for Parkinson’s Therapy The study, published in eLife https://lnkd.in/ez3qChkz, investigated the role of lysosomal positioning in the autophagy-lysosome pathway for enhancing the degradation of abnormal alpha-synuclein (aSyn). They identified compounds that promote lysosomal clustering around the microtubule-organizing center (MTOC), leading to increased autophagic flux. Notably, albendazole, one such compound, enhanced the degradation of aSyn aggregates in a cellular PD model. These findings suggest that lysosome-clustering compounds hold promise as a therapeutic strategy for neurodegenerative diseases. #genetics #Genomics #precisionmedicine #genomicmedicine #brain #neurology #neurodegeneration #neuroscience #parkinson #drugdiscovery #drugdevelopment #drugs #autophagy #lysosome #aging #longevity #therapeutics #biotechnology #innovation #research #science #sciencecommunication

Epilepsy is a mosaic of very different types of epilepsies, which are slow-evoluting neurodegenerative diseases. Many epilepsies have multiple component origins (genetic and/or epigenetic). It is of value to have in hands epilepsy models that both work in vitro and in vivo for a better drug candidate evaluation. Pilocarpine is one of them and you can get it at NEUROSERVICES-ALLIANCE. Pilocarpine induces epileptiform activities in vitro in our model.

𝗔𝗘𝗗 𝗿𝗲𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗰𝗼𝗺𝗽𝗼𝘂𝗻𝗱 𝘀𝘁𝘂𝗱𝘆 𝘀𝗲𝗿𝗶𝗲𝘀: #𝟭 - 𝗣𝗶𝗹𝗼𝗰𝗮𝗿𝗽𝗶𝗻𝗲 At Neuroservices-Alliance, we specialize in analyzing the effects of potential antiepileptic drugs (AEDs). Pilocarpine, a compound widely used to induce seizures in preclinical models, is crucial for studying epilepsy and testing new AEDs. Our data shows that Pilocarpine significantly increases epileptiform discharge (ED) rate while decreasing ED amplitude, underscoring its effectiveness in modeling chronic epilepsy in rats. These insights are vital for developing treatments aimed at controlling severe seizures.   🔎 Curious about how we can assist with your AED studies? Contact us to learn more about our expertise and how we can support your research: contact@neuroservices-alliance.com   🔗 Consult our dedicated article for more insights: https://lnkd.in/gp285eJn #Epilepsy #Neuroscience #CNS #Research #drugdiscovery #Pilocarpine

The Gut Microbiota in Parkinson Disease: Interactions with Drugs and Potential for Therapeutic Applications "This article, published in CNS drugs https://lnkd.in/eV57yfQj, summarises the most up-to-date knowledge in pharmacomicrobiomics in PD, and discusses how the manipulation of gut microbiota represents a potential new therapeutic avenue for PD." It's a must. #genetics #genomics #microbiome #gutbrainaxis #precisionmedicine #genomicmedicine #brain #neurology #neuroscience #neurodegeneration #parkinson #drugs #drugdevelopment #drugdesign #therapeutics #clinicalresearch #biotechnology #innovation #research #science #sciencecommunication

🔬 Advancements in Epilepsy Research: Unveiling Insights into EPM7 🌐 Scientists create a mouse model for EPM7, a progressive seizure disorder, identifying key brain cells and testing a drug for potential treatment. A promising step forward in epilepsy understanding. #Neuroscience #EpilepsyTreatment #ResearchBreakthrough

Exciting announcement this morning! We are thrilled to announce PUR501 as our lead candidate for a novel non-hallucinogenic neuroplastogen! PUR501, an orally bioavailable serotonin 2A (5-HT2A) receptor partial agonist, has shown promising results in promoting neuroplasticity without inducing hallucinations. Key Highlights: 🔹 Positive effects on structural neuroplasticity 🔹 Minimal hallucinogenic capacity 🔹 Safe cardiac profile Our CEO and co-founder, Janet Qi, shared, "Selecting PUR501 as our lead development candidate marks a significant milestone. We are excited to commence IND-enabling activities in late 2024, aiming to establish a new treatment paradigm for neurocognitive impairment." Stay tuned for more updates as we complete preclinical development and prepare for IND submission! Check out the full press release! Link in bio. #PurMindsNeuroPharma #Neuroplasticity #InnovativeTherapies #Neuroscience #NeurodegenerativeDiseases #PharmaceuticalResearch